ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour |
rdf:type |
node1 |
ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour |
rdf:type |
rdfs:Resource |
ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour |
rdf:type |
owl:Thing |
ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour |
rdf:type |
prov:Person |
ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour |
rdf:type |
foaf:Person |
ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour |
rdf:type |
ripe:AuthorAuthor |
ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour |
owl:sameAs |
https://semopenalex.org/author/A5054689715 |
ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour |
http://www.w3.org/ns/org#memberOf |
ripekg:organization/RIPEO331FE219A098399ECancer Research Center |
ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour |
foaf:familyName |
Cheraghpour |
ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour |
foaf:givenName |
Makan |
ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour |
foaf:name |
Makan Cheraghpour |
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial |
dcterms:creator |
ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour |